RLYB Stock Overview
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rallybio Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.96 |
| 52 Week High | US$3.46 |
| 52 Week Low | US$0.84 |
| Beta | -1.55 |
| 1 Month Change | -17.95% |
| 3 Month Change | -11.93% |
| 1 Year Change | -60.00% |
| 3 Year Change | -89.67% |
| 5 Year Change | n/a |
| Change since IPO | -93.19% |
Recent News & Updates
Recent updates
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully
Aug 28
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
Jan 04Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
Sep 19Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
May 15We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth
Jan 30Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Oct 31Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Jul 07Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans
Mar 16Shareholder Returns
| RLYB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.0% | -2.7% | -2.6% |
| 1Y | -60.0% | -6.2% | 23.1% |
Return vs Industry: RLYB underperformed the US Biotechs industry which returned -5% over the past year.
Return vs Market: RLYB underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| RLYB volatility | |
|---|---|
| RLYB Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RLYB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RLYB's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 25 | Steve Uden | www.rallybio.com |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Rallybio Corporation Fundamentals Summary
| RLYB fundamental statistics | |
|---|---|
| Market cap | US$38.54m |
| Earnings (TTM) | -US$66.97m |
| Revenue (TTM) | US$598.00k |
66.6x
P/S Ratio-0.6x
P/E RatioIs RLYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLYB income statement (TTM) | |
|---|---|
| Revenue | US$598.00k |
| Cost of Revenue | -US$5.50m |
| Gross Profit | US$6.10m |
| Other Expenses | US$73.07m |
| Earnings | -US$66.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 1,019.40% |
| Net Profit Margin | -11,199.50% |
| Debt/Equity Ratio | 0% |
How did RLYB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 22:50 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rallybio Corporation is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Eun Kyung Yang | Jefferies LLC |
| Jonathan Wolleben | JMP Securities |